Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.278 SEK | -1.75% | -3.86% | -7.54% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 81.85 | 534.7 | 310.1 | 1,070 | 1,223 | - | - |
Enterprise Value (EV) 1 | 81.85 | 534.7 | 310.1 | 1,029 | 1,235 | 1,368 | 1,223 |
P/E ratio | -9.69 x | - | -11.9 x | -21.8 x | -24.2 x | -25.6 x | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | -35.7 x | -11.3 x | -23.1 x | -29 x | -33.6 x | -33.3 x |
EV / FCF | - | - | -4.07 x | -27.9 x | -16.5 x | - | - |
FCF Yield | - | - | -24.6% | -3.59% | -6.07% | - | - |
Price to Book | - | 3.14 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 40,219 | 105,262 | 137,515 | 233,775 | 280,980 | - | - |
Reference price 2 | 2.035 | 5.080 | 2.255 | 4.575 | 4.354 | 4.354 | 4.354 |
Announcement Date | 21-02-25 | 22-02-09 | 23-02-22 | 24-02-21 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -14.99 | -27.51 | -44.64 | -42.65 | -40.74 | -36.7 |
EBIT 1 | - | -15.01 | -27.52 | -44.65 | -42.66 | -40.74 | -36.7 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -16.25 | -27.65 | -48.11 | -49.42 | -41.84 | -36.7 |
Net income 1 | -16.02 | -16.25 | -27.65 | -48.11 | -49.42 | -41.84 | -36.7 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -0.2100 | - | -0.1900 | -0.2100 | -0.1800 | -0.1700 | - |
Free Cash Flow 1 | - | - | -76.15 | -36.92 | -75 | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 21-02-25 | 22-02-09 | 23-02-22 | 24-02-21 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 11.7 | 145 | - |
Net Cash position 1 | - | - | - | 40.5 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -0.2754 x | -3.561 x | - |
Free Cash Flow 1 | - | - | -76.2 | -36.9 | -75 | - | - |
ROE (net income / shareholders' equity) | - | - | -14.9% | -19.8% | -46% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | 1.620 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 21-02-25 | 22-02-09 | 23-02-22 | 24-02-21 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.50% | 116M | |
+18.34% | 124B | |
+15.06% | 109B | |
-6.39% | 23.84B | |
+0.99% | 22.42B | |
-14.57% | 17.5B | |
-41.64% | 16.43B | |
-12.07% | 16.61B | |
+1.05% | 13.4B | |
+25.87% | 11.47B |
- Stock Market
- Equities
- CRNO B Stock
- Financials Cereno Scientific AB